A major study led by Dr. Henry Burch and The GRADE Study Research Group has provided important new information about how well different medications help manage type 2 diabetes when used alongside metformin, the most common first-line treatment.
The research, published in *The New England Journal of Medicine*, looked at how four FDA-approved medications work in combination with metformin to control blood sugar levels. The goal was to find out which combination keeps blood sugar in the target range for the longest time.
The study included 5,047 participants from different racial and ethnic backgrounds, all of whom were already taking metformin for their diabetes. They were randomly assigned to one of four groups, with each group receiving one additional medication: sitagliptin, liraglutide, glimepiride, or insulin glargine U-100.
Over the course of about four years, the results showed that people taking liraglutide or insulin glargine along with metformin were able to maintain their target blood sugar levels the longest. These two medications kept blood sugar levels in control for about six months longer than sitagliptin, which turned out to be the least effective of the four.
A key strength of the study was its diverse participant group, which included people of all ages, sexes, races, and ethnicities. The results showed that the effectiveness of the drugs did not differ much among these groups, meaning the findings are likely useful for a wide variety of patients.
Despite the success of some drug combinations, the study also highlighted a big challenge: nearly 75% of the participants were unable to maintain their target blood sugar levels over the four-year period. This shows how hard it can be to manage type 2 diabetes over the long term and the need for better or additional treatment options.
The researchers also studied how these medications affected heart health. They found that people taking liraglutide had the lowest risk of developing cardiovascular problems, such as heart attacks or strokes. This suggests that liraglutide not only helps manage blood sugar but also offers added protection for the heart.
This large and well-designed study gives doctors and patients valuable information about which medication combinations work best with metformin. It also reminds us that while current treatments can help, more research is needed to improve long-term diabetes care and reduce the risks of serious health problems.
For people living with type 2 diabetes, this study shows the importance of finding the right medication combination. It also highlights the need to monitor blood sugar regularly and work closely with healthcare providers to adjust treatment as needed.
In summary, combining metformin with either liraglutide or insulin glargine appears to be the most effective approach for long-term blood sugar control and may also provide added heart benefits. These findings are an important step toward better treatment strategies for managing type 2 diabetes.
If you care about diabetes, please read studies about Potatoes: friend or foe in the battle against diabetes? and findings of This blood pressure drug may protect kidney health in people with diabetes.
For more information about diabetes, please read studies about Scientists find a promising treatment for type 2 diabetes and findings of Certain type 2 diabetes treatment may bring heart risks.
Copyright © 2025 Knowridge Science Report. All rights reserved.
